Silence Therapeutics Could Rival Amgen And Novartis With siRNA Therapy
Early Results Attract Big Pharma Interest
The UK biotech could have a major gene silencing drug on its hands but will need a big pharma partner to help it realize the candidate’s potential.
You may also be interested in...
The siRNA drug demonstrated a significant reduction in lipoprotein(a) from baseline of up to or greater than 90% for the majority of doses in a Phase II trial; Novartis has a potential first-to-market advantage.
The UK major is getting access to Silence's small interfering RNA (siRNA) platform while the London-based biotech is getting further validation of its technology and a considerable pile of cash.
Bepirovirsen made the hepatitis B virus undetectable in nearly 30% of patients in a Phase II study – but it remains to be seen whether this response be sustained once treatment with the novel antisense product ends.